Menu Search
Equities

Immunovia AB (publ)

IMMNOV:STO

Immunovia AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.625
  • Today's Change0.005 / 0.81%
  • Shares traded1.52m
  • 1 Year change-69.20%
  • Beta2.5422
Data delayed at least 15 minutes, as of Nov 08 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Immunovia AB (publ) had net income fall 84.09% from a loss of 168.09m to a larger loss of 309.44m despite a 37.55% increase in revenues from 1.15m to 1.58m.
Gross margin-6,702.03%
Net profit margin-13,120.79%
Operating margin-12,469.94%
Return on assets-93.50%
Return on equity-153.82%
Return on investment-133.56%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Immunovia AB (publ) fell by 29.25m. Cash Flow from Financing totalled 114.74m or 7,285.27% of revenues. In addition the company used 147.06m for operations while cash from investing totalled 3.20m.
Cash flow per share-1.19
Price/Cash flow per share--
Book value per share0.2162
Tangible book value per share0.1914
More ▼

Balance sheet in SEKView more

Immunovia AB (publ) appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.72% of the market capitalization can be attributed to its 76.79m and debt could be paid in full if management chose.
Current ratio1.10
Quick ratio--
Total debt/total equity0.4417
Total debt/total capital0.3064
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.